Patricia Banks

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 199 citations

Medicine, Oncology, Pharmacology +16

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

Mitchell G. Lawrence, Daisuke Obinata, Shahneen Sandhu et al. · European Urology · 2018 · 119 citations · Full text

Medicine, Oncology, Urology +14

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M. Joshua, Louise Emmett et al. · Journal of Clinical Oncology · 2023 · 78 citations

Medicine, Nuclear Medicine, Pharmacology +17

PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M. Joshua, Louise Emmett et al. · Journal of Clinical Oncology · 2022 · 60 citations

Medicine, Oncology, Pharmacology +17

Bevacizumab as a steroid‐sparing agent during immunotherapy for melanoma brain metastases: A case series

Patricia Banks, Arian Lasocki, Peter K. H. Lau et al. · Health Science Reports · 2019 · 50 citations · Full text

Medicine, Oncology, Pharmacotherapy +17